Impact of Aspirin Use on Mortality and Cardiac Allograft Vasculopathy After Heart Transplantation: A Systematic Review and Meta-analysis.
Noémie Fournier, Panagiotis Antiochos, Baris Gencer et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined whether aspirin use was associated with mortality and cardiac allograft vasculopathy (CAV)-related outcomes in heart transplant recipients. It included five observational studies: four adult cohorts and one pediatric cohort. Aspirin use was associated with lower all-cause mortality across four studies (HR 0.31 [95% CI: 0.15-0.67]). The analysis found no statistically significant association with CAV-related clinical outcomes, defined as graft dysfunction or CAV-related death (HR 0.42 [95% CI: 0.10-1.77]). The authors caution that observational evidence cannot establish efficacy.
Key findings
- Across four studies, aspirin use was associated with lower all-cause mortality (HR 0.31 [95% CI: 0.15-0.67]).
- Aspirin use was not significantly associated with CAV-related clinical outcomes (HR 0.42 [95% CI: 0.10-1.77]).
- The review included five observational studies: four adult cohorts and one pediatric cohort.
Why it matters
CAV is an important cause of late graft failure and morbidity after heart transplantation, yet evidence for aspirin’s clinical benefit remains limited. The mortality association is clinically notable, but the absence of a significant association with CAV-related outcomes and the observational evidence base mean the findings should be interpreted cautiously rather than as proof of benefit.
What to keep in mind
The evidence came from observational studies and was subject to substantial heterogeneity and potential residual and time-related biases.